FIELD: medicine, pharmaceutics.
SUBSTANCE: group of inventions refers to medicine, namely otorhinolaryngology and may be used for treating internal ear disorders. That is ensured by using a 1-aminoalkylcyclohexane derivative specified in neramexane or its pharmaceutically acceptable salt. Said derivative is introduced according to the titration schedule which involves increasing a dose of neramexane and gradually increasing a dose by 25 mg or 12.5 mg every week over a period of four to five weeks to achieve an effective daily dose of 50 to 75 mg. What is also presented is using the 1-aminoalkylcyclohexane derivative specified in neramexane or its pharmaceutically acceptable salt, and a method of treating internal ear disorders in an individual in need thereof.
EFFECT: group of inventions enables the fast and safe achievement of the effective dose of neramexane with side effects herewith minimised.
14 cl, 9 dwg, 10 tbl, 8 ex
| Title | Year | Author | Number |
|---|---|---|---|
| 1-AMINOALKYLCYCLOHEXANE DERIVATIVES FOR TREATING COCHLEAR TINNITUS | 2008 |
|
RU2438658C2 |
| INTERVAL THERAPY FOR TREATING TINNITUS | 2008 |
|
RU2446794C2 |
| 1-AMINOALKYLCYCLOHEXANE DERIVATIVES FOR TREATING AND PREVENTING HEARING LOSS | 2008 |
|
RU2452476C2 |
| NEW COMBINATIONS OF NERAMEXANE FOR TREATING NEURODEGENERATIVE DISORDERS | 2008 |
|
RU2432161C1 |
| 1-AMINOALKYLCYCLOHEXANE DERIVATIVES FOR TREATMENT OF INFLAMMATORY SKIN DISEASES | 2009 |
|
RU2481828C2 |
| DERIVATIVES OF 1-AMINO-ALKYLCYCLOHEXANE FOR TREATMENT OF DISEASES, MEDIATED BY MAST CELLS | 2009 |
|
RU2484813C2 |
| MATRIX TABLET WITH MODIFIED NERAMEXANE RELEASE | 2006 |
|
RU2422135C2 |
| METHODS AND COMPOSITIONS FOR TREATING PRESBYOPIA, MYDRIASIS AND OTHER OCULAR DISORDERS | 2019 |
|
RU2824137C2 |
| APPLICATION OF ERIBULIN IN CANCER TREATMENT | 2015 |
|
RU2699545C2 |
| METHOD OF TREATING THERMOREGULATION DISORDER | 2007 |
|
RU2478379C2 |
